Rhenium-188: W-188 Generator and Therapy

Rhenium-188 (Re-188) is a generator-produced, high-energy beta-emitting therapy radionuclide that also emits an imageable 155 keV gamma, so a single isotope can both treat disease and be imaged for dosimetry. Because Re-188 is eluted on demand from a long-lived tungsten-188/rhenium-188 generator rather than shipped as a unit dose, a facility that uses it must plan its physics, imaging, shielding, waste handling, and patient-release workflow around the generator — not around a fixed delivery schedule.

Re-188 is not a mainstream agent in most U.S. nuclear medicine departments, but it illustrates a set of physics and radiation-safety principles that recur across the therapy radionuclides DRPS supports, including the parent-daughter generator chemistry, high-energy beta dosimetry, bremsstrahlung shielding, and the single-isotope "image-and-treat" model. This article explains how the generator works, what Re-188's emissions mean for dose and imaging, where it has been used clinically, and how a facility should frame the radiation-safety program.

Introduction

A therapy radionuclide generator separates a short-lived, useful daughter from a longer-lived parent so the daughter can be drawn off ("eluted") whenever it is needed. The best-known example in nuclear medicine is the molybdenum-99/technetium-99m generator, which supplies the diagnostic workhorse Tc-99m. The tungsten-188/rhenium-188 (W-188/Re-188) generator applies the same principle to a therapy radionuclide.¹²

Re-188 is attractive for therapy because it emits a high-energy beta particle that deposits dose over a short range in tissue, and because it simultaneously emits a modest 155 keV gamma that a conventional gamma camera can image. That combination makes it a single-isotope theranostic agent: the treatment dose and the imaging signal come from the same atoms.¹³

For a medical physicist or radiation safety officer (RSO), the interesting part is not the chemistry alone but the consequences. A long-lived parent changes how often doses are prepared and how waste decays. A high-energy beta changes shielding and dosimetry. A low-abundance imaging gamma changes how post-therapy images are acquired. This article walks through each of those, the way DRPS does when supporting a facility's PET/CT and nuclear medicine physics program.

Topic Explanation

What is the W-188/Re-188 generator?

The W-188/Re-188 generator is an alumina-column device from which carrier-free Re-188 is eluted as sodium perrhenate using saline. The parent, tungsten-188, is adsorbed onto an aluminum-oxide (Al₂O₃) column. Tungsten-188 decays by beta emission to Re-188, which is washed off the column in the chemical form perrhenate, ¹⁸⁸ReO₄⁻, when saline is passed through it. The chemistry and column design are directly analogous to the Mo-99/Tc-99m generator used every day in nuclear medicine.¹²

Two features set the W-188/Re-188 generator apart:

The parent is hard to make. Tungsten-188 is produced by double neutron capture on enriched tungsten-186 targets in a very high-flux reactor. Only a small number of reactors worldwide can reach adequate specific activity, which has historically limited supply.³
The eluate can be dilute. Because the W-188 on the column is of relatively low specific activity (on the order of 185 GBq, or under 5 Ci, per gram of tungsten), the eluted perrhenate can have a low radioactive concentration. Post-elution concentration techniques are often used to raise the concentration enough for radiopharmaceutical preparation.³

For background on how parent-daughter generators reach equilibrium, see our explainer on the Mo-99/Tc-99m generator and transient equilibrium and on generator quality control for the Ge-68/Ga-68 system.

Why does the long parent half-life matter?

The parent tungsten-188 has a long half-life, on the order of 69 days, while Re-188 has a half-life of only about 16.9 hours.¹² That large ratio is the whole point of the generator: the column keeps regenerating Re-188 for months, so a single generator can be eluted repeatedly over a useful life of roughly four to six months.³ The practical effect is that Re-188 behaves like an in-house, on-demand therapy isotope rather than a shipped unit dose — but the cost is that the facility, not a vendor, owns the generator's quality control, decay, and eventual disposal.

Key Technical Principles

Re-188 emission properties

The table below summarizes the physical properties that drive every downstream decision. The values are the canonical decay figures reported in the Re-188 literature.¹³

Parameter	Value	Why it matters
Parent (W-188) half-life	~69 days	Long generator shelf life (~4–6 months) ²³
Re-188 half-life	~16.9 hours	On-demand elution; fast patient and waste decay ¹
Principal β⁻ maximum energy	2.12 MeV (~71% of decays)	Therapeutic dose; drives bremsstrahlung ¹³
Second β⁻ branch	1.965 MeV (~26% of decays)	Adds to the high-energy beta output ³
Imaging gamma	155 keV (~15% abundance)	Gamma-camera imaging and dosimetry ¹³
Decay product	Stable osmium-188	No long-lived radioactive daughter ¹
Eluate chemical form	Sodium perrhenate (¹⁸⁸ReO₄⁻) in saline	Labeling chemistry; QC target ¹

The beta particles do the therapeutic work. A beta with a maximum energy of about 2.12 MeV has a maximum range on the order of a centimeter in soft tissue (with a much shorter mean range), so dose is deposited locally around where the agent concentrates. The 155 keV gamma is a relatively low-abundance emission, but it falls in a convenient energy window for a standard gamma camera, which is what makes post-therapy imaging and image-based dosimetry possible with the therapy agent itself.¹³

Secular equilibrium and ingrowth after elution

Because the parent half-life is far longer than the daughter half-life, the W-188/Re-188 pair sits in secular equilibrium: over the hours that matter for a single elution, the parent activity is effectively constant, and the Re-188 activity on the column rebuilds toward a maximum set by the parent. After a complete elution (which leaves essentially no Re-188 on the column), the daughter activity grows back as:

A_{Re} (t) = A_{Re}^{m a x} (1 - e^{- λ_{Re} t})

where the decay constant is

λ_{Re} = \frac{ln 2}{T _{1/2}} = \frac{0.693}{16.9 h} \approx 0.0410 h^{- 1} .

Working a practical example, the fraction of the maximum Re-188 activity available 24 hours after a full elution is:

\frac{A _{Re} ( 24 )}{A _{Re}^{m a x}} = 1 - e^{- (0.0410) (24)} = 1 - e^{- 0.984} \approx 0.63.

So a generator eluted one day and left overnight has only recovered to roughly 63% of its maximum output. One half-life (about 16.9 hours) after elution the column has rebuilt to 50%; by two half-lives it reaches about 75%; and after roughly four half-lives (about 2.5 days) it is above 90%. A facility planning a dosing day has to schedule elutions around this ingrowth curve, exactly as a Tc-99m generator is managed for transient equilibrium. The difference is that the Re-188 column, backed by a ~69-day parent, keeps doing this for months.¹²

Clinical Impact

Re-188 has been studied across several therapy applications, almost all of them exploiting the high-energy beta for local dose and the 155 keV gamma for imaging. The three best-documented uses are bone-pain palliation, intra-arterial liver therapy, and radiosynovectomy.

Bone-pain palliation (Re-188-HEDP)

Re-188 bound to a diphosphonate (HEDP) concentrates in osteoblastic bone metastases and delivers local dose. In a dose-escalation study in prostate cancer patients with painful bone metastases, the maximum tolerated activity of Re-188-HEDP was about 3.3 GBq (with the dose-limiting toxicity being reversible thrombocytopenia), and pain palliation was reported in roughly 60–75% of patients.⁴ A systematic review of bone-seeking radiopharmaceuticals for castration-resistant prostate cancer placed Re-188-HEDP among the agents producing pain response rates greater than about 50–60%.⁵ For the broader category, see our overview of bone-pain palliation radiopharmaceuticals.

Inoperable hepatocellular carcinoma (Re-188-lipiodol)

Re-188 conjugates mixed with lipiodol and delivered through the hepatic artery have been studied for inoperable hepatocellular carcinoma (HCC). An International Atomic Energy Agency–sponsored multinational phase II trial treated 185 patients across eight countries, prescribing activity from a scout dose to keep absorbed dose below organ limits (lungs under 12 Gy, normal liver under 30 Gy, bone marrow under 1.5 Gy). The approach was feasible and relatively inexpensive, requiring no patient isolation, which is a notable advantage over iodine-131 lipiodol.⁶ An earlier multicenter study of transarterial Re-188 HDD-lipiodol in inoperable primary HCC reported similar feasibility and safety using the same scout-dose, organ-limit methodology.⁷

Radiosynovectomy

For chronic inflammatory joint disease refractory to conventional therapy, intra-articular Re-188 colloid has been used to ablate inflamed synovium. In a prospective series, 555 MBq of Re-188 tin colloid injected into the knee produced a clinical response in the large majority of treated joints, with shorter disease duration predicting better response.⁸

Across all three applications, the clinical value tracks the physics: a high-energy beta for local ablative dose, a short half-life that limits the duration of the radiation-safety burden, and a 155 keV gamma that lets the team confirm where the dose actually went.

Practical Optimization Tips

A facility considering or operating a Re-188 program should treat it as a generator-based therapy program, with the following practical points.

1. Manage the generator like a therapy asset

Schedule elutions around the ingrowth curve so that the needed activity is actually available at dosing time.
Track the generator's remaining useful life; the long parent half-life is an advantage, but output per elution still declines over months as the parent decays.
Plan post-elution concentration if the labeling chemistry needs higher radioactive concentration than the raw eluate provides.³

2. Run eluate quality control every time

Routine QC mirrors other medical generators and should follow the generator-specific guidance and the facility's written procedures:²

Radionuclidic purity — check for W-188 parent breakthrough, the analog of Mo-99 breakthrough in a Tc-99m generator.
Radiochemical purity — confirm the activity is in the intended perrhenate form.
Alumina (aluminum) content and pH — confirm column integrity and that the eluate is suitable for labeling.

3. Shield for betas and bremsstrahlung

High-energy betas generate bremsstrahlung X-rays when they stop in dense material, so the shielding order matters:

Attenuate the betas first with a low-atomic-number material (such as acrylic or plastic).
Then use lead to attenuate the bremsstrahlung X-rays and the 155 keV gamma.

A shield designed as if Re-188 were a pure beta emitter will underestimate the external photon field. See our discussion of beta and bremsstrahlung shielding for high-energy beta emitters and specific gamma-ray constants for point-source dose estimates.

4. Use the 155 keV gamma for dosimetry

The imaging gamma lets the team acquire post-therapy gamma-camera images to verify biodistribution and support image-based internal dosimetry with the therapy agent itself. This is the single-isotope theranostic advantage and should be built into the protocol rather than treated as optional. For the underlying methods, see our overviews of conjugate-view planar quantification and voxel-based dosimetry for radiopharmaceutical therapy.

Regulatory Considerations

A Re-188 therapy program is governed by the same radioactive-material framework as other unsealed byproduct therapies, and the generator adds the obligations of in-house source production. The relevant frameworks for a U.S. medical-use program are:

10 CFR Part 20 — Standards for Protection Against Radiation, which sets occupational and public dose limits that become the design goals for shielding and operational controls.⁹
10 CFR Part 35 — Medical Use of Byproduct Material, which governs authorized use, written directives, and the RSO's responsibilities for therapy radionuclides.¹⁰
10 CFR 35.75 and NRC Regulatory Guide 8.39, which govern patient release. A patient may be released when the total effective dose equivalent to any other individual is not likely to exceed 5 mSv (0.5 rem), and written radiation-safety instructions are required when that dose could exceed 1 mSv (0.1 rem). The Re-188 release calculation should use the short physical half-life and the agent's biodistribution.¹¹¹²

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control regulations, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license and which written-directive, survey, waste, and reporting requirements apply before relying on any assumption. Generator-specific technical guidance such as IAEA Technical Reports Series No. 470 describes the W-188/Re-188 and Sr-90/Y-90 generators in detail and is a useful reference for QC expectations.² These programs are a core part of DRPS radioactive material license support and radiation safety officer consulting. For the general release framework, see our guide to patient release after radiopharmaceutical therapy.

Frequently Asked Questions (FAQs)

What is rhenium-188?

Rhenium-188 (Re-188) is a therapy radionuclide obtained from a tungsten-188/rhenium-188 generator as carrier-free sodium perrhenate. It emits a high-energy beta particle (maximum energy about 2.12 MeV) that delivers therapeutic dose and a 155 keV gamma photon (about 15% abundance) that can be imaged, so it can be used to both treat and image.

Why is Re-188 produced from a generator instead of a cyclotron?

Re-188 has a half-life of only about 16.9 hours, which is too short to ship routinely over long distances. Its parent, tungsten-188, has a half-life on the order of 69 days, so a W-188/Re-188 generator can supply fresh Re-188 on demand for roughly four to six months, similar in concept to the Mo-99/Tc-99m generator.

What is Re-188 used to treat?

Reported applications include Re-188-HEDP for painful bone metastases, Re-188-lipiodol for inoperable hepatocellular carcinoma delivered intra-arterially, and Re-188 colloid radiosynovectomy for inflammatory joint disease. Most clinical use has been in early-phase studies rather than large routine programs.

Is Re-188 a theranostic radionuclide?

Yes, in the single-isotope sense. The same Re-188 that delivers beta-particle therapy also emits a 155 keV gamma that a gamma camera can image, so the treatment agent can be imaged for biodistribution and dosimetry without a separate diagnostic radionuclide.

How is Re-188 shielded?

Re-188 emits high-energy beta particles that produce bremsstrahlung in dense materials. Best practice is to attenuate the betas first with a low-atomic-number material and then use lead to attenuate the resulting bremsstrahlung X-rays and the 155 keV gamma. A beta-only shielding assumption underestimates the external photon field.

Can a patient treated with Re-188 be released?

Patient release follows the same framework as other unsealed therapy radionuclides under 10 CFR 35.75 and NRC Regulatory Guide 8.39: a patient may be released when the total effective dose equivalent to any other individual is not likely to exceed 5 mSv, and written instructions are required when that dose could exceed 1 mSv. The short half-life and biodistribution should be used in the release calculation.

What quality control does a W-188/Re-188 generator eluate need?

Routine checks mirror those for other medical generators: radionuclidic purity (W-188 parent breakthrough), radiochemical purity (the perrhenate fraction), alumina content, and pH, in line with the facility's procedures and generator-specific guidance such as IAEA Technical Reports Series No. 470.

Key Takeaways

Re-188 is a generator-produced therapy radionuclide. It is eluted on demand from a W-188/Re-188 alumina column as sodium perrhenate, in direct analogy to the Mo-99/Tc-99m generator.¹²
The physics drives everything. A ~16.9-hour half-life, a ~2.12 MeV maximum-energy beta, and a 155 keV imaging gamma set the dosing cadence, the dose deposition, and the imaging strategy.¹³
The long parent half-life is the advantage. A ~69-day W-188 parent keeps the generator useful for about four to six months, so output must be scheduled around the daughter ingrowth curve.²³
It is a single-isotope theranostic. The 155 keV gamma allows post-therapy imaging and dosimetry with the treatment agent itself.¹³
Shield for betas and bremsstrahlung. Use low-Z material first, then lead for the bremsstrahlung and the 155 keV gamma.¹
The regulatory program is standard byproduct-material practice. Authorized use, written directives, QC, waste, and patient release follow 10 CFR Parts 20 and 35, 10 CFR 35.75, and Regulatory Guide 8.39.⁹¹⁰¹¹¹²

Conclusion

Rhenium-188 is a useful lens on therapy-radionuclide physics even where it is not the agent a facility ultimately uses. Its generator chemistry, high-energy beta dosimetry, bremsstrahlung shielding needs, and single-isotope imaging gamma recur, in different combinations, across the therapy radionuclides that modern nuclear medicine programs increasingly handle. A facility that understands how the W-188/Re-188 generator behaves — the ingrowth curve, the QC checks, the shielding order, the release math — is well positioned to run any generator-based or unsealed-therapy program defensibly.

The medical physicist and RSO should treat Re-188, like any therapy radionuclide, as a workflow problem as much as a chemistry one: match the elution schedule to the dosing day, document QC each time, shield for the full emission spectrum, image the therapy for dosimetry, and tie patient release to the actual physics rather than a generic rule of thumb.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and theranostics facilities translate therapy-radionuclide physics into practical, documented workflows. For generator-based and unsealed-therapy programs, this can include PET/CT and nuclear medicine physics support, shielding and workflow review, dosimetry support, generator and eluate QC program design, waste and decay-in-storage planning, radioactive material license support, and RSO program guidance aligned with NRC and Agreement State requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong therapy-radionuclide program makes the safe process the easy process for the clinical team — from the first elution to patient release.

Related Resources

References

Knapp FF Jr. Rhenium-188 — a generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm. 1998;13(5):337-349. doi:10.1089/cbr.1998.13.337. PubMed
International Atomic Energy Agency. Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re Generators. Technical Reports Series No. 470. Vienna: IAEA; 2009. iaea.org
Pillai MRA, Dash A, Knapp FF Jr. Rhenium-188: availability from the 188W/188Re generator and status of current applications. Curr Radiopharm. 2012;5(3):228-243. doi:10.2174/1874471011205030228. PubMed
Palmedo H, Guhlke S, Bender H, et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med. 2000;27(2):123-130. doi:10.1007/s002590050017. PubMed
van Dodewaard-de Jong JM, Oprea-Lager DE, Hooft L, et al. Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: a systematic review. Eur Urol. 2016;70(3):416-426. doi:10.1016/j.eururo.2015.09.005. PubMed
Bernal P, Raoul JL, Vidmar G, et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys. 2007;69(5):1448-1455. doi:10.1016/j.ijrobp.2007.05.009. PubMed
Sundram F, Chau TCM, Onkhuudai P, Bernal P, Padhy AK. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2004;31(2):250-257. doi:10.1007/s00259-003-1363-2. PubMed
Shamim SA, Kumar R, Halanaik D, et al. Role of rhenium-188 tin colloid radiosynovectomy in patients with inflammatory knee joint conditions refractory to conventional therapy. Nucl Med Commun. 2010;31(9):814-820. doi:10.1097/MNM.0b013e32833d6869. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR 35.75: Release of individuals containing unsealed byproduct material or implants containing byproduct material. nrc.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39: Release of Patients Administered Radioactive Material. Rev. 1. 1997. nrc.gov